Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Augmentin ES-600 · 2 trials · 1 indication
Cmax - Maximum Observed Concentration
AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)
AUC0-t - Area under the concentration-time curve from time zero to the time of last non-zero concentration
Cmax - Maximum Observed Concentration
AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)
AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL | DRUG | 1 x 600 mg/42.9 mg/5 mL, single-dose fed |
| Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension | DRUG | 1 x 600 mg/42.9 mg/5 mL, single-dose fed |
| Augmentin ES-600™ | DRUG | 1 x 600 mg/42.9 mg/5 mL, single-dose fasting |
Inclusion Criteria: * Healthy, non-smoking male or non-pregnant, non-lactating female subjects, 18 years of age and over. * Body weight within ±15% of the appropriate weight range published in 1993 by Metropolitan Life Insurance Company, Statistical Bureau and body-mass index (BMI) less than 30. * ...
Augmentin ES-600 is a small molecule drug being developed by Teva Pharmaceutical Industries Limited (TEVA). It is a suspension formulation containing 600 mg amoxicillin and 42.9 mg clavulanate potassium per 5 mL. It is currently in Phase 1 clinical development for use in healthy volunteers.
Augmentin ES-600 is being studied in healthy volunteers as part of Phase 1 clinical trials. The trials are designed to evaluate the drug under fasting and fed conditions. No specific disease indication has been reported for this drug in the available clinical trial data.
Augmentin ES-600 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting Phase 1 clinical trials for this drug in healthy volunteers.
Augmentin ES-600 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, and the drug is not currently in active clinical trials.
Augmentin ES-600 has been studied in two completed Phase 1 clinical trials: NCT00840099, which evaluated the drug under fasting conditions, and NCT00840840, which evaluated it under fed conditions. Both trials enrolled 48 healthy volunteers each in Canada, with participants aged 18 years and older.
Augmentin ES-600 is a specific formulation of amoxicillin and clavulanate potassium, containing 600 mg amoxicillin and 42.9 mg clavulanate potassium per 5 mL suspension. It is being studied as a distinct product by Teva Pharmaceutical Industries Limited in Phase 1 trials.